BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Faslodex fulvestrant regulatory update

The U.K.'s NICE issued final guidance recommending against Faslodex fulvestrant from AstraZeneca as an alternative to aromatase inhibitors to treat estrogen-receptor-positive, locally advanced or metastatic breast cancer in postmenopausal women whose cancer has relapsed or progressed. The...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >